Wells Score for DVT
Estimates the clinical pre-test probability of deep vein thrombosis using 10 bedside criteria. Includes both the original 3-tier model and the validated 2-tier “DVT likely / unlikely” interpretation to guide D-dimer testing and imaging decisions.
Calculate Wells Score for DVT
Select the clinical features present in your patient. The score sums points from 10 criteria (range −2 to 9). Results are displayed using both the traditional 3-tier and modified 2-tier interpretations.
The Wells score was developed for ambulatory outpatients with suspected DVT. It is not validated for hospitalised inpatients, pregnant patients, patients already on anticoagulation, patients with a prior DVT in the same leg within the past 2 years, or those with symptoms lasting longer than 60 days. In these groups, clinical judgement and direct imaging are recommended.
Understanding the Wells Score for DVT
Deep vein thrombosis affects an estimated 1–2 per 1,000 adults annually, and clinical signs alone are neither sensitive nor specific enough for diagnosis. The Wells score was developed by Philip Wells and colleagues in 1997 to formalise the pre-test probability assessment and guide the efficient use of D-dimer testing and compression ultrasonography.
The score combines nine clinical features that increase DVT probability (each worth +1 point) with one feature that reduces it — the presence of an alternative diagnosis at least as likely as DVT (−2 points). This final criterion is the most subjective element but also one of the most powerful discriminators in the model.
Scoring Criteria (+1 each)
1. Active cancer (ongoing or palliative)
2. Paralysis, paresis, or recent cast
3. Bedridden >3 d or surgery ≤12 wk
4. Localised tenderness along deep veins
5. Entire leg swollen
6. Calf swelling >3 cm vs. other leg
7. Pitting oedema (symptomatic leg)
8. Collateral superficial veins (non-varicose)
9. Previously documented DVT
Subtracting Criterion (−2)
Alternative diagnosis at least as likely as DVT: If the clinician considers another diagnosis (e.g., cellulitis, Baker’s cyst, muscle strain, lymphoedema) to be equally or more plausible, 2 points are subtracted from the total.
Worked example: A patient with calf swelling (+1), pitting oedema (+1), and localised tenderness (+1) but a clear cellulitis with erythema and warmth considered equally likely (−2) would score 1 point — “DVT unlikely” on the 2-tier model.
Key distinction — Two interpretation models: The original 1997 Wells model uses a 3-tier system (low, moderate, high). The modified 2-tier model (Wells 2003) simplifies this to “DVT unlikely” (≤1) vs. “DVT likely” (≥2). Current NICE and ACCP guidelines favour the 2-tier model because it integrates more cleanly with D-dimer-based exclusion pathways.
Score Interpretation & Diagnostic Pathway
Traditional 3-Tier Model (Wells 1997)
| Score | Pre-test Probability | DVT Prevalence | Recommended Action |
|---|---|---|---|
| ≤0 | Low | ~5% | D-dimer → if negative, DVT excluded; if positive, ultrasound |
| 1–2 | Moderate | ~17% | D-dimer → if negative, DVT excluded; if positive, ultrasound |
| ≥3 | High | ~53% | Compression ultrasound (D-dimer not sufficient to exclude) |
Modified 2-Tier Model (Wells 2003)
| Score | Category | DVT Prevalence | Recommended Action |
|---|---|---|---|
| ≤1 | DVT Unlikely | ~6% | D-dimer → if negative, DVT safely excluded; if positive, ultrasound |
| ≥2 | DVT Likely | ~28% | Compression ultrasound as first-line investigation |
A negative high-sensitivity D-dimer in a “DVT unlikely” patient (score ≤1) has a negative predictive value exceeding 99%, safely excluding DVT without imaging. However, D-dimer should not be used alone to exclude DVT in “DVT likely” patients (score ≥2), where the false-negative rate is clinically unacceptable. In these patients, proceed directly to compression ultrasonography regardless of D-dimer results.
Differential Diagnosis of Leg Swelling
The “alternative diagnosis as likely” criterion (−2 points) is the most subjective but also one of the most important discriminators in the Wells score. A systematic consideration of alternative diagnoses is essential before scoring.
Cellulitis is one of the most common mimics of DVT and the most frequent alternative diagnosis in patients referred for DVT assessment. Key distinguishing features include well-defined erythema, warmth, tenderness, and occasionally systemic features such as fever and rigors. Cellulitis tends to involve the superficial tissues with a spreading border, whereas DVT produces deeper, more diffuse swelling with less surface erythema.
However, DVT and cellulitis can coexist — venous stasis from DVT predisposes to skin breakdown and secondary infection. If clinical doubt remains, ultrasound should be performed even when cellulitis appears to be the primary diagnosis. Elevated inflammatory markers (CRP, WBC) support cellulitis but do not exclude DVT.
A ruptured Baker’s cyst classically presents with sudden-onset calf pain and swelling, closely mimicking acute DVT. The cyst, a herniation of synovial fluid from the knee joint, dissects along tissue planes when it ruptures, causing distal calf oedema and bruising (the “crescent sign” at the ankle). A history of knee osteoarthritis or inflammatory joint disease is suggestive.
Ultrasound of the popliteal fossa reveals the cyst and can simultaneously assess for DVT, which may coexist or be caused by cyst-related venous compression. MRI is the most definitive investigation if the diagnosis remains uncertain after ultrasound.
Calf muscle tears (typically the medial head of gastrocnemius) present with acute-onset pain during exertion, localised tenderness, and sometimes bruising. Unlike DVT, there is usually a clear precipitating event, and the tenderness is muscular rather than along the deep venous distribution. Palpation may reveal a palpable defect in the muscle belly.
Intramuscular haematoma from anticoagulation or trauma can cause swelling and tenderness that overlaps clinically with DVT. Ultrasound can differentiate muscle pathology from venous thrombosis and should be considered when clinical uncertainty exists, particularly in patients with additional DVT risk factors.
Lymphoedema produces chronic, non-pitting oedema that typically progresses gradually over weeks to months. Primary lymphoedema affects younger patients (often female), while secondary lymphoedema results from surgery, radiotherapy, infection, or malignancy involving lymph nodes. Stemmer’s sign (inability to pinch the skin at the base of the second toe) is suggestive of lymphoedema.
Unlike DVT, lymphoedema is typically painless and involves the dorsum of the foot — whereas DVT-related swelling usually spares the foot. Chronic lymphoedema can cause skin changes (hyperkeratosis, papillomatosis) that are not seen in acute DVT. New-onset unilateral lymphoedema in an older patient should prompt investigation for pelvic or inguinal malignancy.
Post-thrombotic syndrome (PTS) affects 20–50% of patients after a DVT and can produce chronic leg swelling, pain, heaviness, skin discolouration, and venous ulceration. These symptoms overlap significantly with acute recurrent DVT, making diagnosis challenging. The Villalta scale can help quantify PTS severity.
Patients with prior DVT who present with worsening symptoms require careful evaluation: the Wells score gives +1 for previous DVT, but an acute recurrence must be differentiated from progression of PTS. Serial compression ultrasound comparing current findings with a baseline post-DVT scan (ideally obtained 3–6 months after the initial event) is the most reliable approach.
Superficial venous thrombosis (SVT) presents with a palpable, tender, erythematous cord along a superficial vein. While historically considered benign, SVT involving the great saphenous vein within 3 cm of the saphenofemoral junction carries a significant risk (~15%) of concurrent or subsequent DVT extension. Ultrasound should be performed in these cases to assess for deep venous involvement.
Anticoagulation (typically fondaparinux or prophylactic-dose LMWH for 45 days) is recommended for extensive SVT (>5 cm length) or SVT near the saphenofemoral junction. Isolated short-segment SVT in a varicose vein can usually be managed with NSAIDs and compression.
When evaluating a swollen leg, always ask: (1) Is the onset acute or chronic? (2) Is it unilateral or bilateral? (3) Is there pitting or non-pitting oedema? (4) Is there erythema, warmth, or skin changes? (5) Are there systemic signs (fever, tachycardia)? These five questions rapidly narrow the differential and inform appropriate Wells scoring.
Special Populations & Considerations
The Wells score was derived and validated in ambulatory outpatients presenting with suspected DVT. Its performance may differ in several important populations where the pre-test probability or D-dimer characteristics are altered.
Recurrent DVT: Diagnosing recurrent DVT in a previously affected leg is challenging because residual vein thrombus persists in up to 50% of patients at 1 year. A new DVT can only be reliably diagnosed if the residual vein diameter has increased by ≥4 mm compared with a baseline scan, or a new non-compressible venous segment is identified. Always compare with prior imaging if available.
Systematic Diagnostic Approach
The following step-by-step pathway integrates the Wells score with D-dimer testing and compression ultrasound in the evaluation of suspected DVT. This approach follows NICE, ACCP, and ASH guideline recommendations.
Assess the patient at the bedside using all 10 Wells criteria. Take particular care with the “alternative diagnosis” criterion — actively consider and document at least one plausible alternative before deciding to subtract 2 points. The score should be calculated before any laboratory or imaging investigations are ordered.
Ensure the patient falls within the validated population: ambulatory outpatient, not pregnant, not already anticoagulated, symptoms present <60 days. If not, consider proceeding directly to imaging.
For patients with a Wells score ≤1 (“DVT unlikely”), a high-sensitivity D-dimer test is the next step. If the D-dimer is negative (<500 µg/L, or below the age-adjusted threshold for patients >50 years), DVT can be safely excluded without imaging — the 3-month thromboembolic risk is <1%.
If the D-dimer is positive, proceed to compression ultrasonography. Remember that D-dimer has many causes of false positives: infection, inflammation, malignancy, pregnancy, recent surgery, and age. A positive D-dimer does not diagnose DVT — it simply means imaging is needed.
For patients with a Wells score ≥2 (“DVT likely”), compression ultrasonography should be the first-line investigation. D-dimer testing alone is insufficient to exclude DVT in this group due to the higher pre-test probability and unacceptable false-negative rate.
If ultrasound is positive (non-compressible vein), the diagnosis of DVT is confirmed — initiate anticoagulation. If the initial proximal ultrasound is negative but clinical suspicion remains high, consider: (a) whole-leg ultrasound to assess for isolated distal DVT, (b) D-dimer to help risk-stratify, or (c) repeat proximal ultrasound in 5–7 days to detect propagating thrombus.
Once DVT is confirmed on imaging, anticoagulation should be initiated without delay (ideally within 24 hours). For most patients, this means a DOAC (apixaban or rivaroxaban are preferred as single-drug regimens without LMWH lead-in). For cancer-associated DVT, LMWH or edoxaban/rivaroxaban may be preferred depending on cancer type and bleeding risk.
Duration of anticoagulation depends on whether the DVT was provoked or unprovoked: provoked DVT (surgery, immobilisation) typically requires 3 months, whereas unprovoked DVT or recurrent DVT may warrant extended or indefinite anticoagulation. Assess bleeding risk alongside thrombotic risk when determining duration.
Common Pitfalls & Limitations
The Wells score is one of the most widely validated clinical decision rules in medicine, but it is frequently misapplied. The following pitfalls can lead to diagnostic errors and patient harm.
The −2 point criterion for “alternative diagnosis at least as likely as DVT” is the most subjective element and carries the greatest weight in the score. Studies have shown significant inter-rater variability in how clinicians apply this criterion. Anchoring bias (deciding early that the diagnosis is cellulitis, for example) can lead to premature subtraction of 2 points and false reassurance.
Best practice: Require an explicit, documented alternative diagnosis before subtracting 2 points. The alternative should have identifiable clinical features — not simply “it doesn’t look like DVT.” If there is genuine uncertainty between DVT and another diagnosis, it is safer not to subtract the 2 points and proceed with D-dimer or imaging.
This is a critical safety error. In patients with a Wells score ≥2, a negative D-dimer does not safely exclude DVT. The prevalence of DVT in this group is approximately 28%, and the false-negative rate of D-dimer at this pre-test probability is clinically unacceptable. These patients must undergo compression ultrasonography regardless of D-dimer results.
This error often occurs in time-pressured emergency departments where D-dimer is ordered reflexively. Clinicians should calculate the Wells score before ordering any investigations so that the D-dimer result is interpreted in the correct clinical context.
The Wells score was derived from ambulatory outpatients presenting to emergency departments and thrombosis clinics. It has not been adequately validated in hospitalised inpatients (where immobility and the base rate of DVT are both higher) or in pregnant patients (where D-dimer is physiologically elevated and iliac DVT is more common).
In hospitalised patients with suspected DVT, bypassing clinical decision rules and proceeding directly to compression ultrasound is recommended. In pregnancy, whole-leg ultrasound including the iliac veins should be the first-line investigation, with MRI venography as an alternative if the diagnosis remains uncertain.
Standard 2-point compression ultrasound evaluates only the common femoral and popliteal veins. Isolated calf (distal) DVT is not detected by this approach and accounts for approximately 20–30% of all DVT. While the clinical significance of isolated distal DVT is debated, untreated distal DVT can propagate proximally in up to 15–25% of cases.
Options for managing a negative proximal ultrasound with ongoing symptoms include: whole-leg ultrasound (increased sensitivity for distal DVT but lower specificity), D-dimer testing (if negative, propagation is unlikely), or serial proximal ultrasound at 5–7 days (the traditional approach to detect proximal propagation). Local protocols vary — be familiar with your institution’s approach.
D-dimer levels rise with age, and a fixed threshold of 500 µg/L leads to a false-positive rate exceeding 60% in patients over 80 years. This results in unnecessary ultrasound examinations, increased healthcare costs, and incidental findings. Age-adjusted D-dimer thresholds (age × 10 µg/L for patients >50 years) have been prospectively validated and shown to reduce unnecessary imaging by approximately 30% without increasing the miss rate.
For example, in a 75-year-old patient with a “DVT unlikely” Wells score, a D-dimer level of 600 µg/L would be considered negative using the age-adjusted threshold (75 × 10 = 750 µg/L) but positive using the fixed 500 µg/L threshold. Several international guidelines now endorse the age-adjusted approach.
Quick Reference Summary
| 2-Tier Score | Category | Next Step | If Negative |
|---|---|---|---|
| ≤1 | DVT Unlikely | D-dimer | DVT excluded (3-month VTE risk <1%) |
| ≥2 | DVT Likely | Compression US | Consider serial US, whole-leg US, or D-dimer to assess further |
The Golden Rule: Calculate the Wells score before ordering any tests. Use D-dimer only when Wells says “unlikely” (≤1). Use ultrasound first when Wells says “likely” (≥2). Never use D-dimer alone to exclude DVT in “DVT likely” patients — this is a patient safety issue.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350(9094):1795–1798. DOI: 10.1016/S0140-6736(97)08140-3
- Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349(13):1227–1235. DOI: 10.1056/NEJMoa023153
- Wells PS, Owen C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis? JAMA. 2006;295(2):199–207. DOI: 10.1001/jama.295.2.199
- Geersing GJ, Zuithoff NPA, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ. 2014;348:g1340. DOI: 10.1136/bmj.g1340
- Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117–1124. DOI: 10.1001/jama.2014.2135
- National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158). 2020; updated 2023. Available at: nice.org.uk/guidance/ng158
- Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226–3256. DOI: 10.1182/bloodadvances.2018024828
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. DOI: 10.1016/j.chest.2015.11.026
- Stevens SM, Woller SC, Baumann Kreuziger L, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–e608. DOI: 10.1016/j.chest.2021.07.055